Influenza: Page 5

Euroimmun launches test to distinguish between COVID, flu
By LabPulse.com staff writers
The real-time polymerase chain reaction (PCR) diagnostic received the CE Mark, allowing it to be sold in countries that accept the European sign of approval. The test can detect SARS-CoV-2, influenza virus type A, and influenza virus type B, helping physicians better identify the cause of infection in patients with acute symptoms.
December 13, 2020
2020 06 15 18 14 5259 Swab Sample Collection 400
Eurofins debuts combined tests for COVID-19, flu, RSV
By LabPulse.com staff writers
The combined SARS-CoV-2 plus flu A/B and RSV tests aim for the qualitative detection of SARS-CoV-2 and the quantitative detection of influenza A, influenza B, and RSV. The combined COVID-19 and flu test now can be ordered as individual tests.
November 17, 2020
2020 06 29 16 41 7549 Pathogenic Bacteria Viruses 400
LabPulse.com Point-of-Care Insider
By Brian Casey
Dear Point-of-Care Insider,
November 8, 2020
Who should get the 1st COVID-19 vaccines?
By Leah Sherwood
Current strategic prioritization plans emphasize the importance of vaccinating healthcare workers, since doing so preserves the healthcare system itself. Another priority is to directly protect the elderly and people with comorbidities, who are at the highest risk of death or hospitalization from COVID-19.
October 25, 2020
2020 10 24 00 06 5467 Viral Like Particles Vaccine 400
Truvian's COVID-19 antibody test cleared by FDA
By LabPulse.com staff writers
The antibody test offers 98.4% sensitivity and 98.9% specificity, and has been tested and validated by healthcare professionals and scientists at the University of California, San Diego (UCSD) and the University of Chicago, according to the company. Furthermore, company evaluation suggests no cross-reactivity with HIV, influenza A and B, and several coronavirus strains, Truvian said.
July 29, 2020
2020 06 17 20 35 0417 Covid 19 Antibody 400
Scientists urge surveillance of new SARS-CoV-2 variant
By Samantha Black, PhD
Coronaviruses have encoded proofreading mechanisms, unlike other pathogenic viruses, and as a result SARS-CoV-2 has very low sequence diversity. However, natural selection can result in favorable mutations that provide an advantage to viral infectivity or transmission. Antigenic single amino acid changes are observed in seasonal influenza viruses and in previous coronaviruses. For example, a single amino acid change in spike D480A/G in the receptor-binding domain of SARS-CoV became the dominant variant in the later stages of the 2003 to 2004 pandemic.
July 6, 2020
2020 06 17 20 35 0417 Covid 19 Antibody 400
FDA announces flurry of emergency authorizations for COVID-19 products
By LabPulse.com staff writers
Cleared July 2
July 1, 2020
2016 09 02 09 36 05 93 Fda Logo V2 400
GenMark releases new rapid respiratory infection panel test
By LabPulse.com staff writers
The company's ePlex Respiratory Pathogen 2 (RP2) panel is now available in the U.S. for distribution and use. Earlier this month, GenMark requested an emergency use authorization for the panel with the U.S. Food and Drug Administration.
June 28, 2020
2020 06 29 16 41 7549 Pathogenic Bacteria Viruses 400
Sengenics launches antibody test for past, present COVID-19 exposure
By LabPulse.com staff writers
The lab-based biochip test can identify epitopes, titers, and immunoglobulin class and subclass antibodies. The test identifies patients with current or past SARS-CoV-2 infection, according to the company.
June 24, 2020
2020 04 16 18 56 8041 Virus Coronavirus Sars Co V 2 400
Cue gets FDA clearance for point-of-care coronavirus test
By LabPulse.com staff writers
The Cue Health COVID-19 molecular test detects SARS-CoV-2 nucleic acid from a nasal swab sample. It runs a 25-minute analysis directly at the point of care and delivers the results to the Cue mobile app.
June 14, 2020
2020 03 04 00 35 9478 Smartphone Hands 400
BioIQ, P23 launch home saliva panel test for COVID-19, flu
By LabPulse.com staff writers
The diagnostic tests for the novel coronavirus, influenza viruses, rhinoviruses, adenovirus, and more. It can help distinguish between symptomatic patients who need treatment for COVID-19 versus another type of respiratory ailment, a feature that will become increasingly important during the upcoming flu season.
June 14, 2020
2020 03 20 23 29 9036 Virus Coronavirus Microscope 400
Quidel builds point-of-care respiratory infection panel with BARDA cash
By LabPulse.com staff writers
The funding will support the development of a point-of-care diagnostic assay that tests for SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus. The respiratory virus panel would run on Quidel's Sofia 2 flagship instrument.
June 11, 2020
2019 08 05 19 10 8249 Dollar Sign 400
Previous Page
Page 5 of 7
Next Page